Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$201.68 USD

201.68
5,108,724

+1.21 (0.60%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $200.01 -1.67 (-0.83%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Curis (CRIS) Skyrockets on Promising Phase I Pipeline Updates

Curis' (CRIS) hematologic malignancy candidate, CA-4948, shows promising activity in early-stage studies evaluating it in patients with either acute myeloid leukemia or non-Hodgkin's lymphoma. Stock up 350%.

Kinjel Shah headshot

Pharma Stock Roundup: Approval of PFE/BNTX Coronavirus Vaccine in UK, Other Updates

Pfizer (PFE) COVID-19 vaccine gets approval for emergency use in the United Kingdom while Roche's (RHHBY) Xolair gets FDA nod for new indication.

The Zacks Analyst Blog Highlights: Facebook, Netflix, AbbVie, American Airlines and Micron Technology

The Zacks Analyst Blog Highlights: Facebook, Netflix, AbbVie, American Airlines and Micron Technology

AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier

AbbVie (ABBV) signs a global deal with Frontier Medicines to make innovative therapies and E3 degraders against difficult-to-drug targets.

Sheraz Mian headshot

Top Stock Reports for Facebook, Netflix & AbbVie

Today's Research Daily features new research reports on 16 major stocks, including Facebook, Inc. (FB), Netflix, Inc. (NFLX) and AbbVie Inc. (ABBV).

Tracey Ryniec headshot

3 Top Lessons Learned from Buffett's 2020 Portfolio Moves

During a global pandemic, Berkshire Hathaway has re-tooled its portfolio. Maybe it's time you do the same?

Zacks Value Trader Highlights: Southwest, JPMorgan, Wells Fargo, Apple and AbbVie

Zacks Value Trader Highlights: Southwest, JPMorgan, Wells Fargo, Apple and AbbVie

AbbVie (ABBV) Up 30% Since Last Earnings Report: Can It Continue?

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed

Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.

Tracey Ryniec headshot

3 Top Lessons Learned from Buffett's 2020 Portfolio Moves

During a global pandemic, Berkshire Hathaway has re-tooled its portfolio. Maybe it's time you do the same?

Kinjel Shah headshot

Pharma Stock Roundup: AZN COVID-19 Vaccine Interim Data, PFE Emergency Use Appeal

AstraZeneca (AZN) COVID-19 vaccine candidate proves effective in late-stage study. Pfizer (PFE) seeks Emergency use for its COVID-19 vaccine candidate.

Bausch (BHC) Begins Second Phase III Study on NOV03 for DED

Bausch (BHC) starts a second phase III study on its investigational treatment NOV03 for dry eye disease related to Meibomian gland dysfunction.

The Zacks Analyst Blog Highlights: AbbVie, Square, Honda Motor, Canadian Pacific Railway and Wayfair

The Zacks Analyst Blog Highlights: AbbVie, Square, Honda Motor, Canadian Pacific Railway and Wayfair

Is AbbVie (ABBV) a Suitable Stock for Value Investors Now?

Let's see if AbbVie Inc. (ABBV) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Kinjel Shah headshot

Pharma Stock Roundup: PFE Coronavirus Data, FDA Emergency Tag for LLY COVID-19 Drug

Eli Lilly (LLY) and Pfizer (PFE) provide updates on their coronavirus vaccine/antibody candidates.

Mark Vickery headshot

Top Analyst Reports for AbbVie, Square & Honda Motor

Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Square, Inc. (SQ) and Honda Motor Co., Ltd. (HMC).

Biohaven (BHVN) Q3 Earnings Miss, Nurtec Uptake Promising

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

ImmunoGen (IMGN) Q3 Earnings & Sales Top, Pipeline on Track

ImmunoGen (IMGN) reports encouraging third-quarter results. Top-line data readout from pivotal studies on its lead candidate, mirvetuximab soravtansine, remains on track.

Editas' (EDIT) Earnings Rise Y/Y in Q3, EDIT-101 in Focus

Editas' (EDIT) bottom line grows year over year in the third quarter while revenues beat estimates. Stock rises is after-hours trading.

Ironwood (IRWD) Q3 Earnings Beat on Solid Linzess Sales

Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter.

AbbVie (ABBV) in Focus: Stock Moves 7.4% Higher

AbbVie (ABBV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Neurocrine (NBIX) to Report Q3 Earnings: What's in Store?

Investors are expected to focus on Neurocrine's (NBIX) updates on Ingrezza outlook and its pipeline candidates' progress when it reports third-quarter results.

Company News for Nov 2, 2020

Companies In The News Are: ABBV, HON, CVX, RCL

AbbVie (ABBV) Beats on Q3 Earnings & Sales, Ups 2020 Guidance

AbbVie (ABBV) beats on third-quarter 2020 earnings and revenues. Shares up in pre-market trading.

AbbVie (ABBV) Q3 Earnings and Revenues Top Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 2.91% and 1.83%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?